16 May 2014
Serious muscle damage risk from widely used cholesterol lowering drug very low in general population: Otago research
New Zealanders taking a higher dose of simvastatin, one of the statin drugs used to prevent heart attacks and strokes,
have a greater risk of rhabdomyolysis than people taking a lower dose according to new University of Otago research.
However the condition, in which breakdown of muscle tissue can lead to acute kidney failure, is still very rare in both
groups.
In a new study published in the journal International Journal of Cardiology, the researchers found that people taking 40mg of simvastatin daily were about five times as likely to develop
rhabdomyolysis when compared with people taking 20mg daily.
In absolute terms, the risks were about 11 per 100,000 person-years in people taking 40mg simvastatin and 2 per 100,000
person-years in those taking 20mg.
Study lead investigator Dr Lianne Parkin says recent meta-analyses have clearly shown that the benefits of statins in
preventing major cardiovascular events far outweigh any serious adverse effects associated with their use.
“However, these meta-analyses were based on highly selected participants in randomised controlled trials and there was
very little information about the risk of rhabdomyolysis in people taking the doses of simvastatin that are recommended
for use in New Zealand,” Dr Parkin says.
“While previous research has found a greater risk of serious muscle damage in people taking higher doses of statins, our
study is the largest investigation to date of rhabdomyolysis in a general population of simvastatin users and the first
to provide separate estimates of risk for 40mg and 20mg simvastatin.”
The researchers used routinely collected health and prescription medicine data to conduct a study based on 313,552
people of all ages who were dispensed simvastatin at any time between 2005 and 2009. Other factors, including age, sex,
medical conditions, and other prescription drugs, were taken into account in the analyses.
“Statins are one of the most widely used classes of drugs,” says Dr Parkin, “and it is reassuring to have found a very
low risk of rhabdomyolysis in New Zealanders using simvastatin. The greater risk associated with the use of 40mg
simvastatin is one of several factors which patients and their doctors might consider when discussing the balance of
benefits and risks of cholesterol-lowering treatment, and the most appropriate dose and type of statin to be used.”
The research was funded by Medsafe and the Health Research Council of New Zealand.
Publication details:
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data.
ENDS